CTI BioPharma Corp.
|Number of Estimates|
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Market Cap: 64.7 Million
Primary Exchange: NASDAQ
Shares Outstanding: 58 Million
Float: 53.4 Million
Sector: Health Technology
Industry: Pharmaceuticals: Other
Short Interest (Jan 12, 2018): 434 Thousand
Longest drawdown: 1507 trading days
From: 2014-01-21 To: 2019-11-12
CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
via: PR Newswire at 2019-06-13 03:00:00:000
SEATTLE , June 13, 2019 /PRNewswire/ --CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the JMP Securities Life Sciences Conference at 2:00 p.m. EDT in New York City . Presentation details: About… read more...
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|